Top Gabapentin Brands Worth Considering for Quality and Trust

Gabapentin has become an essential medication for managing neuropathic pain and other nervous system disorders. When it comes to choosing the right brand, factors such as efficacy, availability, and patient reviews often play significant roles in the decision-making process. Several brands have consistently met the required standards of quality and reliability, earning the trust of both patients and healthcare providers alike. To discover which brands stand out in the realm of gabapentin, take a closer look at the comprehensive list provided below.

Illustration of gabapentin

Best brands of gabapentin in 2025

Neurontin

Neurontin, a brand of gabapentin, is a leading medication in the treatment of partial-onset seizures and neuropathic pain, having gained FDA approval in 1993. It became available as a generic in 2004 but continues to hold a significant market share, particularly for certain indications. In 2019, gabapentin, often prescribed under the Neurontin brand, was the seventh most prescribed drug in the United States, with 69 million prescriptions dispensed. The North American market, dominated by the U.S., accounts for approximately 33.7% of the global gabapentin market revenue. Neurontin's efficacy and relatively benign adverse effect profile have contributed to its widespread use. For more detailed information on gabapentin, visit the DrugBank resource.

Horizant

Horizant, a brand of gabapentin enacarbil, is a leading producer of this anticonvulsant drug, primarily prescribed for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults. It is administered orally in extended-release tablets, available in 300 mg and 600 mg strengths. The drug has been evaluated in clinical trials, including a Phase 2 study by the National Institute on Alcohol Abuse and Alcoholism, although it did not show significant efficacy for alcohol use disorder. Horizant's formulation ensures a stable release of gabapentin, enhancing patient compliance. The market for gabapentin, including Horizant, is projected to grow at a CAGR of 3.82% to 5.2% from 2024 to 2030, driven by increasing prevalence of neurological disorders. For more detailed information about Horizant, visit their Horizant drug page.

Gralise

Gralise, a brand of gabapentin, is renowned for its effectiveness in managing postherpetic neuralgia, a type of pain that follows shingles. Approved by the FDA in January 2011, Gralise is available in 300 mg and 600 mg tablets and has been a significant player in the gabapentin market, which is projected to grow at a CAGR of 5.2% from 2025 to 2030. In 2019, Assertio Therapeutics sold Gralise to Alvogen for a total transaction value of $127.5 million, highlighting its market value. Gralise has a positive impact on patients, with 58% of reviewers reporting a positive effect on Drugs.com. This brand continues to be a trusted option for healthcare providers treating neuropathic pain. For more detailed information on its FDA approval, you can view the FDA approval documentation.

Gabarone

Gabapentin, a medication primarily used to treat epilepsy, neuropathic pain, and other conditions, is produced by several key players, including Pfizer, Sun Pharmaceutical Industries, Mylan, and Teva Pharmaceutical Industries. Among these, Teva Pharmaceutical Industries is notable for its significant market presence. The gabapentin market, valued at $2.11 billion in 2023, is expected to grow at a CAGR of 5.3% to reach $3.54 billion by 2033, driven by the increasing prevalence of neurological disorders and a rising geriatric population. The market growth is also supported by the preference for capsules, which are likely to remain the preferred form through 2033. Despite challenges such as strict regulatory policies and side effects, the market is anticipated to expand due to strategic initiatives by manufacturers and the growing demand for generics.

Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is a leading producer of gabapentin, having received tentative FDA approval for Gabapentin Enacarbil Extended-Release Tablets in 2020, which are generic versions of Horizant® with annual sales of approximately $99.5 million. The company's global presence and research-led approach position it as a significant player in the gabapentin market, which is expected to grow at a CAGR of 6.6% from 2023 to 2032. Glenmark's portfolio includes 167 products authorized for distribution in the U.S. and 44 pending ANDA approvals, highlighting its robust pipeline. The company's focus on generics, specialty, and OTC business across over 50 countries underscores its commitment to providing effective medications like gabapentin. Glenmark's inclusion in the Dow Jones Sustainability Index further emphasizes its corporate sustainability and industry leadership. For more information, visit their official website.

Teva Pharmaceuticals

Teva Pharmaceutical Industries Ltd. is a leading producer of gabapentin, contributing significantly to the global market. As of 2023, the global gabapentin market, in which Teva is a major player, is valued at approximately USD 2.9 billion and is expected to grow at a CAGR of 6.6% until 2032, reaching USD 5.1 billion. Teva's gabapentin products are available in various forms, including tablets and capsules, and are widely used for treating conditions such as epilepsy, neuropathic pain, and restless legs syndrome. North America, where Teva has a strong presence, holds about 37.2% of the global gabapentin market share. The company's commitment to quality and efficacy has made its gabapentin products a preferred choice among healthcare providers.

Actavis

Actavis, now part of Allergan, is a prominent producer of gabapentin, known for its high-quality formulations that meet stringent regulatory standards. The company's gabapentin products are widely prescribed due to their efficacy in managing neuropathic pain and epilepsy, with the global gabapentin market, including Actavis's contributions, projected to grow at a CAGR of 6.12% from 2024 to 2033, reaching USD 4.95 billion by 2033. In the U.S., Actavis's gabapentin market share is significant, with the U.S. market expected to reach USD 1,320 million by 2033, growing at a CAGR of 6.64%. The preference for Actavis's gabapentin is also driven by its favorable safety profile compared to opioids, contributing to the market's robust growth. The availability of generic gabapentin from Actavis has made the drug more affordable and accessible, further boosting its demand. For more details, visit Allergan's gabapentin product page.

Mylan

Mylan N.V. is a prominent player in the global gabapentin market, known for its high-quality and therapeutically equivalent generic formulations. As one of the major key players, Mylan contributes significantly to the market growth, which is projected to reach USD 4.95 billion by 2033, growing at a CAGR of 6.12% from 2024 to 2033. Mylan's gabapentin products are widely prescribed for conditions such as neuropathic pain and epilepsy, capitalizing on the increasing prevalence of these conditions. The company's strong presence in the market is further bolstered by its extensive distribution network and competitive pricing. North America, where Mylan has a substantial market share, accounts for about 37.2% of the global gabapentin market.

Lupin Pharmaceuticals

Lupin Pharmaceuticals is a prominent player in the gabapentin market, known for its high-quality formulations and significant market presence. The company is part of a global market that is expected to grow at a CAGR of 6.6% from 2023 to 2032, reaching a market size of approximately USD 5.1 billion by 2032. Lupin's contribution to the market is notable, especially in regions like North America and the Asia Pacific, where the demand for gabapentin is increasing due to the rising prevalence of neurological disorders. The company's products are widely prescribed for conditions such as neuropathic pain and epilepsy, reflecting its strong position in the pharmaceutical sector. With a robust distribution network and favorable regulatory environments, Lupin continues to be a key player in the gabapentin market. For more information, explore their gabapentin products.

Aurobindo Pharma

Aurobindo Pharma is a prominent player in the gabapentin market, known for its high-quality generic and branded formulations. The company's gabapentin products are widely used for treating neuropathic pain and epilepsy, contributing to the market's growth with a CAGR of over 5% from 2023 to 2035. Aurobindo Pharma's strong presence in regions like North America and Asia Pacific, where healthcare spending is high, such as the US with healthcare expenses of around USD 3 trillion in 2021, further boosts its market share. The company's products are available in various dosage forms, including tablets, capsules, and oral solutions, catering to diverse patient needs. As the global gabapentin market is projected to reach USD 6 billion by 2035, Aurobindo Pharma remains a key contributor to this growth. Learn more about their high-quality gabapentin products.